Citigroup Inc. Has $11.96 Million Holdings in Illumina, Inc. $ILMN

Key Points

• Citigroup Inc. increased its stake in Illumina, Inc. by 13.5%, acquiring a total of 150,764 shares valued at approximately $11.96 million.
• Illumina's stock has been the subject of mixed analyst ratings, with a consensus average rating of "Hold" and a price target of $124.58, while Citigroup downgraded its rating from "hold" to "strong sell."
• Illumina reported quarterly earnings of $1.19 per share, surpassing expectations, but its revenue decreased by 4.8% year-over-year, amounting to $1.06 billion.

Citigroup Inc. raised its stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 13.5% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 150,764 shares of the life sciences company's stock after purchasing an additional 17,985 shares during the period. Citigroup Inc. owned 0.10% of Illumina worth $11,962,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of ILMN. Townsquare Capital LLC grew its position in shares of Illumina by 23.5% during the 4th quarter. Townsquare Capital LLC now owns 16,196 shares of the life sciences company's stock valued at $2,164,000 after buying an additional 3,087 shares during the last quarter. Sagespring Wealth Partners LLC bought a new stake in shares of Illumina during the 4th quarter valued at about $225,000. Mariner LLC grew its position in shares of Illumina by 13.5% during the 4th quarter. Mariner LLC now owns 10,921 shares of the life sciences company's stock valued at $1,459,000 after buying an additional 1,298 shares during the last quarter. CreativeOne Wealth LLC bought a new stake in shares of Illumina during the 4th quarter valued at about $248,000. Finally, Jump Financial LLC grew its position in shares of Illumina by 260.0% during the 4th quarter. Jump Financial LLC now owns 7,865 shares of the life sciences company's stock valued at $1,051,000 after buying an additional 5,680 shares during the last quarter. Institutional investors own 89.42% of the company's stock.

Illumina Trading Up 0.9%

Shares of ILMN stock traded up $0.89 during trading hours on Tuesday, reaching $101.42. 251,150 shares of the stock traded hands, compared to its average volume of 2,347,143. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $156.66. The business has a fifty day moving average price of $97.12 and a 200 day moving average price of $89.34. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $15.59 billion, a PE ratio of 12.85, a PEG ratio of 2.25 and a beta of 1.37.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.02 by $0.17. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The business had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same quarter in the previous year, the business earned $0.36 earnings per share. The firm's revenue was down 4.8% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. On average, equities research analysts forecast that Illumina, Inc. will post 4.51 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on ILMN shares. Daiwa Capital Markets lowered shares of Illumina from an "outperform" rating to a "neutral" rating and set a $94.00 target price for the company. in a research note on Tuesday, August 12th. Barclays boosted their target price on shares of Illumina from $85.00 to $90.00 and gave the company an "underweight" rating in a research note on Friday, August 1st. Piper Sandler reduced their target price on shares of Illumina from $190.00 to $185.00 and set an "overweight" rating for the company in a research note on Thursday, May 15th. Morgan Stanley boosted their target price on shares of Illumina from $100.00 to $105.00 and gave the company an "equal weight" rating in a research note on Monday, August 4th. Finally, Stephens set a $110.00 price target on shares of Illumina and gave the stock an "overweight" rating in a research note on Monday, August 4th. Seven investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $124.58.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.